To evaluate the effect of proteasome inhibition on intracellular RhoA-GTP, which can serve as a surrogate for DLC1 tumor suppressor activity, A549 cells were treated for 24 h with Ixazomib alone followed by another 24 h of Ixazomib treatment together with the AKT inhibitor MK-2206 and/or the SRC inhibitor Saracatinib, and the RhoA-GTP level was determined (Fig. 1c). Here, RHOA is linked to neoplasm.